Third, although CAR T cell targeting GPC-3 therapy for advanced HCC patients is considered next-generation immunotherapy, our study did not directly evaluate the efficacy of CAR T cell therapy. This evidence concerns the gene GPC3 and hepatocellular carcinoma.